Liability · Informed consent · 2026-05-24

Informed consent as the strongest route

In practice the informed-consent route is by far the strongest legal avenue. Not because the treatment is per se unlawful, but because the patient can claim that — given full information — they would have chosen otherwise. That is the informed-consent counterfactual.

The Wgbo (art. 7:448 BW) requires honest information on the nature and purpose of treatment, expected effects and risks, alternatives, and health status. Below are five elements where that duty in practice often falls short — with sources.

1. Uncertainty about effectiveness

When international reviews rate the evidence quality as very low, that is a material fact. NICE (2020)1 rated the evidence on puberty blockers as very low certainty, SBU (2022)2 judged the evidence on hormone treatment insufficient, and the Cass Review (2024)3 called gender care for young people "an area of remarkably weak evidence". A physician who presents the treatment as safe and effective, while structural doubt persists in the international literature, breaches the duty of disclosure. It cannot be the case that the Dutch physician does not know this debate — or, knowing it, withholds it from the patient.

2. Irreversibility — the pause-button myth

Puberty blockers are often presented as a pause button. The data say otherwise. In the Dutch cohort of Brik et al. (2020), 87% of adolescents who started puberty blockers had moved on to cross-sex hormones after a median of 0.8 years on blockers and 6% had discontinued the blockers; the authors note that this may reflect eligibility criteria that select those highly likely to pursue further treatment.4 The Cass Review reports progression of 93% and 98% in two further Amsterdam studies and 98% (43 of 44) in the UK early intervention study (Carmichael et al. 2021)5 (source). In these cohorts most adolescents who started blockers went on to hormones, so presenting blockers purely as a pause button gives an incomplete picture.

Add to this the effects on bone density6, which in the Amsterdam studies fall during puberty suppression and in part catch up under later hormone treatment (source), effects on cognition and fertility that the Dutch Health Council considers insufficiently studied (source), and — for transgender girls who start GnRH analogues in early puberty — in principle infertility unless they are willing to stop treatment for a long time. Surgical interventions are of course definitive.

3. Fertility loss

For transgender girls, GnRH analogues started in early puberty in principle lead to infertility unless they are willing to stop treatment for a long time; in a very small number of treated girls sperm freezing was still not possible for most after more than 1.5 years of discontinuation. For transgender boys, research on fertility preservation exists only as case reports, from which egg preservation appears possible (Dutch Health Council 2026, source). The adolescent is thus placed before a decision with lifelong consequences that, as the Cass Review writes, is "uniquely difficult" for children to make themselves (source).

A physician facilitating this decision without accounting for the fact that a young adolescent may find it hard to grasp the impact of possible permanent infertility stands legally weak. "But the parents also signed" does not cover this: the child is the patient, and the child bears the consequences for life.

4. The existence of alternatives

The Wgbo requires disclosure of alternative treatment options, including watchful waiting. In the follow-up study of Wallien & Cohen-Kettenis (2008), of 77 children referred to a gender clinic at a mean age of 8.4, 27% were still gender dysphoric at follow-up (age 16 or older) and 43% no longer were; 30% could not be traced or did not take part (source). Steensma et al. (2013) found that the intensity of gender dysphoria in childhood is associated with persistence into adolescence.7 These are small cohorts of clinic-referred children, so the share of children whose gender dysphoria goes away cannot be tied to a single figure. When this is not discussed, or when affirmative treatment is presented as the only option, the duty of disclosure is breached.

5. Comorbidity and differential diagnosis

Among adolescents presenting for gender care, co-occurring conditions are common: in the first two years of the Finnish adolescent gender identity service, severe psychopathology preceding the onset of gender dysphoria was common and autism spectrum problems were very common (Kaltiala-Heino 2015, source), and the Cass Review discusses high levels of neurodiversity and other co-occurring conditions.8 When these are not first thoroughly diagnosed and treated, it is unclear whether gender dysphoria is the primary problem or a secondary symptom. A physician who does not exercise this diligence breaches the second disciplinary norm.

Causation and damage: what must be proven?

For a successful civil claim the chain must be established: breach, hypothetical alternative decision (counterfactual), damage. For disciplinary law, the breach in principle suffices.

  • The breach: missing or misleading information, deficient diagnostics, failure to discuss alternatives, ignoring comorbidity, following an outdated guideline without critical review.
  • The counterfactual: would the patient — or, in the case of a minor, the parents, or the now-adult child looking back — have chosen otherwise given full information?
  • The damage: physical (osteoporosis, infertility, sexual dysfunction, surgical complications, lifelong medication dependence), psychological (regret, depression, identity crisis), social (relationships, desire for children, work disability).

Notes

  1. NICE. Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria. October 2020 (pdf).
  2. SBU. Hormone treatment of children and adolescents with gender dysphoria (report 342). February 2022 (sbu.se).
  3. Cass H. The Cass Review — Final Report. NHS England, April 2024.
  4. Brik T, Vrouenraets LJJJ, de Vries MC, Hannema SE. Trajectories of adolescents treated with gonadotropin-releasing hormone analogues for gender dysphoria. Archives of Sexual Behavior. 2020;49(7):2611–2618.
  5. Carmichael P, Butler G, Masic U, et al. Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. PLOS ONE. 2021;16(2):e0243894.
  6. Schagen SEE, Wouters FM, Cohen-Kettenis PT, Gooren LJ, Hannema SE. Bone development in transgender adolescents treated with GnRH analogues and subsequent gender-affirming hormones. J Clin Endocrinol Metab. 2020;105(12):e4252–e4263.
  7. Wallien MSC, Cohen-Kettenis PT. Psychosexual outcome of gender-dysphoric children. J Am Acad Child Adolesc Psychiatry. 2008;47(12):1413–1423; Steensma TD, McGuire JK, Kreukels BPC, Beekman AJ, Cohen-Kettenis PT. Factors associated with desistence and persistence of childhood gender dysphoria: a quantitative follow-up study. J Am Acad Child Adolesc Psychiatry. 2013;52(6):582–590; for review see Ristori J, Steensma TD. Gender dysphoria in childhood. Int Rev Psychiatry. 2016;28(1):13–20.
  8. de Vries ALC, Noens ILJ, Cohen-Kettenis PT, van Berckelaer-Onnes IA, Doreleijers TA. Autism spectrum disorders in gender dysphoric children and adolescents. J Autism Dev Disord. 2010;40(8):930–6; Kaltiala-Heino R, Sumia M, Työläjärvi M, Lindberg N. Two years of gender identity service for minors. Child Adolesc Psychiatry Ment Health. 2015;9:9.